Collexis Announces Market Leader Position in Scientific Grant Analysis

Collexis Holdings Inc.Collexis Holdings Inc. (OTCBB: CLXS), a leading developer of semantic search and knowledge discovery software, announced today that they are becoming the global leader in grant analysis and grant management tools in the sciences. With the recent launch of the National Institutes of Health (NIH) Categorization project, and the ongoing projects with leading private research funders, Collexis is analyzing over $20B in grant funds annually in the life sciences alone. Collexis expects their penetration within the grant management business segment to significantly grow in 2009.

"The largest public and private funders of biomedical research use Collexis to analyze their grant content," said Bill Kirkland, CEO of Collexis. "The largest public funder is our NIH project for disease categorization, and the largest private funder is our project for Wellcome Trust in the United Kingdom. We have similar projects with smaller funding organizations and we are seeing increased interest from research funders outside of the health sciences. This really puts us in the leadership position in the workflow and analysis of the scientific grant management process."

"This position is a great compliment to our leadership in Biomedical Expertise Profiling," said Dr. Christian Herzog, general manager for Collexis science, technical, and medical business. "We are now releasing products that intersect our knowledge of scientists with grant and literature sources - so we can automatically recommend the top global or regional reviewers for grants and journal manuscripts."

The recently launched Collexis Reviewer Finder is the first product version of Collexis tools that leading research institutions use to assign reviewers to grants. The system has 1.8 Million Expert profiles pre-loaded and automatically identifies co-author and institutional conflicts of interest. The Collexis Reviewer Finder system is being deployed selectively within the NIH, several large publishing partners, and other grant-funding agencies. The system also utilizes Collexis Expertise Profiles which are enterprise solutions for Johns Hopkins, Mayo Clinic, the NIH, and over 25 other leading academic medical institutions worldwide.

Related news articles:

About Collexis Holdings, Inc.
Collexis Holdings, Inc., a leading developer of high definition search and knowledge discovery software is headquartered in Columbia, South Carolina (USA) with major operations in Cincinnati, Ohio, Geldermalsen, the Netherlands and Cologne, Germany. Collexis now offers the world's first pre-populated scientific social network for life science researchers, www.biomedexperts.com. Collexis' proprietary technology builds conceptual profiles of text, called Fingerprints, from documents, Websites, emails and other digitized content and matches them with a comprehensive list of pre-defined "fingerprinted" concepts to make research results more relevant and efficient. This matching of concepts eliminates the ambiguity and lack of priority associated with word searches. The results are often described as "finding needles in many haystacks." Through this novel approach, Collexis can build unique applications to search, index and aggregate information as well as prioritize, trend and predict data based on sources in multiple industries without the limitations of language or dialect. Collexis' current clients in the public, private and academic sectors include the Mayo Clinic; Johns Hopkins University; Dana-Farber Cancer Institute, the University of California, San Francisco; the University of South Carolina; Erasmus University Library; Bristol-Myers Squibb; Lockheed Martin; the World Health Organization; Wellcome Trust; the National Institutes of Health; and the U.S. Department of Defense. Shares of Collexis common stock are traded under the symbol CLXS on the OTC Bulletin Board (OTC BB). For more information, visit www.collexis.com.

Most Popular Now

New Training Year Starts at Siemens Heal…

In September, 197 school graduates will start their vocational training or dual studies in Germany at Siemens Healthineers. 117 apprentices and 80 dual students will begin their careers at Siemens...

Digital ECGs at Barts Health: A High-Imp…

Opinion Article by Dr Krishnaraj Sinhji Rathod, consultant in interventional cardiology, Barts Health NHS Trust. Picture the moment. A patient in an ambulance, enroute to hospital with new chest pain. Paramedics...

New AI Tool Addresses Accuracy and Fairn…

A team of researchers at the Icahn School of Medicine at Mount Sinai has developed a new method to identify and reduce biases in datasets used to train machine-learning algorithms...

Global Study Reveals How Patients View M…

How physicians feel about artificial intelligence (AI) in medicine has been studied many times. But what do patients think? A team led by researchers at the Technical University of Munich...

Study Sheds Light on Hurdles Faced in Tr…

Implementing artificial intelligence (AI) into NHS hospitals is far harder than initially anticipated, with complications around governance, contracts, data collection, harmonisation with old IT systems, finding the right AI tools...

Using Deep Learning for Precision Cancer…

Altuna Akalin and his team at the Max Delbrück Center have developed a new tool to more precisely guide cancer treatment. Described in a paper published in Nature Communications, the...

New AI Approach Paves Way for Smarter T-…

Researchers have harnessed the power of artificial intelligence (AI) to tackle one of the most complex challenges in immunology: predicting how T cells recognize and respond to specific peptide antigens...

Study Used AI Models to Improve Predicti…

Chronic kidney disease (CKD) is a complex condition marked by a gradual decline in kidney function, which can ultimately progress to end-stage renal disease (ESRD). Globally, the prevalence of the...

AI-Powered CRISPR could Lead to Faster G…

Stanford Medicine researchers have developed an artificial intelligence (AI) tool to help scientists better plan gene-editing experiments. The technology, CRISPR-GPT, acts as a gene-editing “copilot” supported by AI to help...

Groundbreaking AI Aims to Speed Lifesavi…

To solve a problem, we have to see it clearly. Whether it’s an infection by a novel virus or memory-stealing plaques forming in the brains of Alzheimer’s patients, visualizing disease processes...

AI Spots Hidden Signs of Depression in S…

Depression is one of the most common mental health challenges, but its early signs are often overlooked. It is often linked to reduced facial expressivity. However, whether mild depression or...